Serum β-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia

Jose Rodriguez, Jorge Cortes, Moshe Talpaz, Susan O'Brien, Terry L. Smith, Mary Beth Rios, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Our objective was to investigate the prognostic significance of serum β-2 microglobulin (B2M) levels among patients with chronic myelogenous leukemia (CML). All patients with Philadelphia chromosome-positive early chronic phase CML (i.e., within 1 year of diagnosis) treated with IFN α- based therapy at the M.D. Anderson Cancer Center between 1980 and 1997, in whom pretreatment B2M levels were available, were investigated. Two hundred one patients were evaluable. Their median B2M was 2.2 mg/dl (range, 1.1-20 mg/dl). Serum B2M levels were associated with other variables of prognostic significance, including age, spleen size, WBC count, percentage of peripheral and marrow blasts, and percentage of marrow basophils. Patients with B2M levels >2.9 mg/dl (i.e., the upper quartile of the distribution) had a significantly lower rate of major cytogenetic response compared to those in the lower three quartiles (20 versus 52%; P < 0.01). They also had a shorter survival, with a 5-year survival rate of 48%, compared with 75% for those in the lower quartiles (P = 0.01). High B2M levels (>2.9 mg/dl) could identify a group of patients with an adverse outcome within patients in stage I disease (P = 0.02). Results for patients in stages 2-4 were inconclusive because of the small number of patients in these groups. We conclude that serum B2M levels are an important, and probably independent, prognostic factor for patients with CML in early chronic phase treated with IFN-based therapy.

Original languageEnglish (US)
Pages (from-to)147-152
Number of pages6
JournalClinical Cancer Research
Volume6
Issue number1
StatePublished - Jan 1 2000
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Serum
Bone Marrow
Leukemia, Myeloid, Chronic Phase
Basophils
Cytogenetics
Spleen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Serum β-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia. / Rodriguez, Jose; Cortes, Jorge; Talpaz, Moshe; O'Brien, Susan; Smith, Terry L.; Rios, Mary Beth; Kantarjian, Hagop.

In: Clinical Cancer Research, Vol. 6, No. 1, 01.01.2000, p. 147-152.

Research output: Contribution to journalArticle

Rodriguez, J, Cortes, J, Talpaz, M, O'Brien, S, Smith, TL, Rios, MB & Kantarjian, H 2000, 'Serum β-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia', Clinical Cancer Research, vol. 6, no. 1, pp. 147-152.
Rodriguez, Jose ; Cortes, Jorge ; Talpaz, Moshe ; O'Brien, Susan ; Smith, Terry L. ; Rios, Mary Beth ; Kantarjian, Hagop. / Serum β-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 1. pp. 147-152.
@article{960c46651f764f30bff182234af5d7f8,
title = "Serum β-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia",
abstract = "Our objective was to investigate the prognostic significance of serum β-2 microglobulin (B2M) levels among patients with chronic myelogenous leukemia (CML). All patients with Philadelphia chromosome-positive early chronic phase CML (i.e., within 1 year of diagnosis) treated with IFN α- based therapy at the M.D. Anderson Cancer Center between 1980 and 1997, in whom pretreatment B2M levels were available, were investigated. Two hundred one patients were evaluable. Their median B2M was 2.2 mg/dl (range, 1.1-20 mg/dl). Serum B2M levels were associated with other variables of prognostic significance, including age, spleen size, WBC count, percentage of peripheral and marrow blasts, and percentage of marrow basophils. Patients with B2M levels >2.9 mg/dl (i.e., the upper quartile of the distribution) had a significantly lower rate of major cytogenetic response compared to those in the lower three quartiles (20 versus 52{\%}; P < 0.01). They also had a shorter survival, with a 5-year survival rate of 48{\%}, compared with 75{\%} for those in the lower quartiles (P = 0.01). High B2M levels (>2.9 mg/dl) could identify a group of patients with an adverse outcome within patients in stage I disease (P = 0.02). Results for patients in stages 2-4 were inconclusive because of the small number of patients in these groups. We conclude that serum B2M levels are an important, and probably independent, prognostic factor for patients with CML in early chronic phase treated with IFN-based therapy.",
author = "Jose Rodriguez and Jorge Cortes and Moshe Talpaz and Susan O'Brien and Smith, {Terry L.} and Rios, {Mary Beth} and Hagop Kantarjian",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
volume = "6",
pages = "147--152",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Serum β-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia

AU - Rodriguez, Jose

AU - Cortes, Jorge

AU - Talpaz, Moshe

AU - O'Brien, Susan

AU - Smith, Terry L.

AU - Rios, Mary Beth

AU - Kantarjian, Hagop

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Our objective was to investigate the prognostic significance of serum β-2 microglobulin (B2M) levels among patients with chronic myelogenous leukemia (CML). All patients with Philadelphia chromosome-positive early chronic phase CML (i.e., within 1 year of diagnosis) treated with IFN α- based therapy at the M.D. Anderson Cancer Center between 1980 and 1997, in whom pretreatment B2M levels were available, were investigated. Two hundred one patients were evaluable. Their median B2M was 2.2 mg/dl (range, 1.1-20 mg/dl). Serum B2M levels were associated with other variables of prognostic significance, including age, spleen size, WBC count, percentage of peripheral and marrow blasts, and percentage of marrow basophils. Patients with B2M levels >2.9 mg/dl (i.e., the upper quartile of the distribution) had a significantly lower rate of major cytogenetic response compared to those in the lower three quartiles (20 versus 52%; P < 0.01). They also had a shorter survival, with a 5-year survival rate of 48%, compared with 75% for those in the lower quartiles (P = 0.01). High B2M levels (>2.9 mg/dl) could identify a group of patients with an adverse outcome within patients in stage I disease (P = 0.02). Results for patients in stages 2-4 were inconclusive because of the small number of patients in these groups. We conclude that serum B2M levels are an important, and probably independent, prognostic factor for patients with CML in early chronic phase treated with IFN-based therapy.

AB - Our objective was to investigate the prognostic significance of serum β-2 microglobulin (B2M) levels among patients with chronic myelogenous leukemia (CML). All patients with Philadelphia chromosome-positive early chronic phase CML (i.e., within 1 year of diagnosis) treated with IFN α- based therapy at the M.D. Anderson Cancer Center between 1980 and 1997, in whom pretreatment B2M levels were available, were investigated. Two hundred one patients were evaluable. Their median B2M was 2.2 mg/dl (range, 1.1-20 mg/dl). Serum B2M levels were associated with other variables of prognostic significance, including age, spleen size, WBC count, percentage of peripheral and marrow blasts, and percentage of marrow basophils. Patients with B2M levels >2.9 mg/dl (i.e., the upper quartile of the distribution) had a significantly lower rate of major cytogenetic response compared to those in the lower three quartiles (20 versus 52%; P < 0.01). They also had a shorter survival, with a 5-year survival rate of 48%, compared with 75% for those in the lower quartiles (P = 0.01). High B2M levels (>2.9 mg/dl) could identify a group of patients with an adverse outcome within patients in stage I disease (P = 0.02). Results for patients in stages 2-4 were inconclusive because of the small number of patients in these groups. We conclude that serum B2M levels are an important, and probably independent, prognostic factor for patients with CML in early chronic phase treated with IFN-based therapy.

UR - http://www.scopus.com/inward/record.url?scp=0033959918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033959918&partnerID=8YFLogxK

M3 - Article

C2 - 10656443

AN - SCOPUS:0033959918

VL - 6

SP - 147

EP - 152

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -